Horm Metab Res 2016; 48(09): 559-564
DOI: 10.1055/s-0042-110491
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Effect of Selenium Supplementation on Recurrent Hyperthyroidism Caused by Graves’ Disease: A Prospective Pilot Study

L. Wang*
1   Department of Endocrinology, the Affiliated Hospital of Qingdao University, Qingdao, China
B. Wang*
1   Department of Endocrinology, the Affiliated Hospital of Qingdao University, Qingdao, China
S. R. Chen*
2   Department of Science and Technology, Jinzhou Medical University, Jinzhou, China
X. Hou
1   Department of Endocrinology, the Affiliated Hospital of Qingdao University, Qingdao, China
X. F. Wang
3   Department of Nuclear Medicine, the Affiliated Hospital of Qingdao University, Qingdao, China
S. H. Zhao
1   Department of Endocrinology, the Affiliated Hospital of Qingdao University, Qingdao, China
J. Q. Song
4   Department of Nursing, Yeda Hospital of Yantai City, Yantai, China
Y. G. Wang
1   Department of Endocrinology, the Affiliated Hospital of Qingdao University, Qingdao, China
› Author Affiliations
Further Information

Publication History

received 07 March 2016

accepted 06 June 2016

Publication Date:
08 July 2016 (online)


The effect of selenium supplementation on recurrent hyperthyroidism caused by Graves’ disease is unclear. Our study aimed to assess the efficacy of selenium supplementation therapy on recurrent Graves’ disease. Forty-one patients with recurrent Graves’ disease were enrolled in this study. All patients received the routine treatment using methimazole (MMI), while patients allocated to the selenium group received additional selenium therapy for 6 months. The influence of selenium supplementation on the concentrations of thyroid stimulating hormone (TSH), anti-TSH-receptor antibodies (TRAb), free thyroxine (FT4), and free triiodothyronine (FT3) were assessed. The remission rate was also compared between 2 groups. There was no obvious difference in the demographic data and the levels of serum FT4, FT3, TSH, and TRAb between the 2 groups at baseline. Both FT4 and FT3 decreased more at 2 months in the selenium group than the controls, while the TSH level increased more in patients receiving selenium supplementation (p<0.05). The TRAb level was significantly lower in patients receiving selenium supplementation (2.4 IU/l vs. 5.6 IU/l, p=0.04). The percentages of patients with normal TRAb level at 6 months was also significantly higher in the selenium group (19.0 vs. 0%, p=0.016). Kaplan-Meier survival curve showed patients receiving selenium supplementation had a significantly higher rate of remission than controls (Log-rank test p=0.008). In conclusion, selenium supplementation can enhance the effect of antithyroid drugs in patients with recurrent Graves’ disease. Randomized trials with large number of participants are needed to validate the finding above.

* L. Wang, B. Wang, and S. R. Chen contributed equally to the study

Supporting Information

  • References

  • 1 Burch HB, Cooper DS. Management of Graves Disease: A Review. JAMA 2015; 314: 2544-2554
  • 2 Morshed SA, Davies TF. Graves’ Disease Mechanisms: The Role of Stimulating, Blocking, and Cleavage Region TSH Receptor Antibodies. Horm Metab Res 2015; 47: 727-734
  • 3 Frank CU, Braeth S, Dietrich JW, Wanjura D, Loos U. Bridge Technology with TSH Receptor Chimera for Sensitive Direct Detection of TSH Receptor Antibodies Causing Graves' Disease: Analytical and Clinical Evaluation. Horm Metab Res 2015; 47: 880-888
  • 4 Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 2013; 9: 724-734
  • 5 Anagnostis P, Adamidou F, Polyzos SA, Katergari S, Karathanasi E, Zouli C, Panagiotou A, Kita M. Predictors of long-term remission in patients with Graves' disease: a single center experience. Endocrine 2013; 44: 448-453
  • 6 Laurberg P. Remission of Graves’ disease during anti-thyroid drug therapy. Time to reconsider the mechanism?. Eur J Endocrinol 2006; 155: 783-786
  • 7 Laurberg P, Krejbjerg A, Andersen SL. Relapse following antithyroid drug therapy for Graves’ hyperthyroidism. Curr Opin Endocrinol Diabetes Obes 2014; 21: 415-421
  • 8 Park SM, Cho YY, Joung JY, Sohn SY, Kim SW, Chung JH. Excessive iodine intake does not increase the recurrence rate of Graves’ disease after withdrawal of the antithyroid drug in an iodine-replete area. Eur Thyroid J 2015; 4: 36-42
  • 9 Piantanida E, Lai A, Sassi L, Gallo D, Spreafico E, Tanda ML, Bartalena L. Outcome Prediction of Treatment of Graves’ Hyperthyroidism with Antithyroid Drugs. Horm Metab Res 2015; 47: 767-772
  • 10 Neumann S, Place RF, Krieger CC, Gershengorn MC. Future Prospects for the Treatment of Graves’ Hyperthyroidism and Eye Disease. Horm Metab Res 2015; 47: 789-796
  • 11 Duntas LH, Benvenga S. Selenium: an element for life. Endocrine 2015; 48: 756-775
  • 12 Kohrle J. Selenium and the thyroid. Curr Opin Endocrinol Diabetes Obes 2015; 22: 392-401
  • 13 Duntas LH. The Role of Iodine and Selenium in Autoimmune Thyroiditis. Horm Metab Res 2015; 47: 721-726
  • 14 Tanda ML, Piantanida E, Lai A, Lombardi V, Dalle Mule I, Liparulo L, Pariani N, Bartalena L. Thyroid autoimmunity and environment. Horm Metab Res 2009; 41: 436-442
  • 15 Marcocci C, Bartalena L. Role of oxidative stress and selenium in Graves’ hyperthyroidism and orbitopathy. J Endocrinol Invest 2013; 36: 15-20
  • 16 Zarkovic M. The role of oxidative stress on the pathogenesis of Graves’ disease. J Thyroid Res 2012; 302537
  • 17 Farrokhian A, Bahmani F, Taghizadeh M, Mirhashemi SM, Aarabi MH, Raygan F, Aghadavod E, Asemi Z. Selenium Supplementation Affects Insulin Resistance and Serum hs-CRP in Patients with Type 2 Diabetes and Coronary Heart Disease. Horm Metab Res 2016; 48: 263-268
  • 18 Puertollano MA, Puertollano E, de Cienfuegos GA, de Pablo MA. Dietary antioxidants: immunity and host defense. Curr Top Med Chem 2011; 11: 1752-1766
  • 19 Marino M, Latrofa F, Menconi F, Chiovato L, Vitti P. Role of genetic and non-genetic factors in the etiology of Graves’ disease. J Endocrinol Invest 2015; 38: 283-294
  • 20 Aihara K, Nishi Y, Hatano S, Kihara M, Yoshimitsu K, Takeichi N, Ito T, Ezaki H, Usui T. Zinc, copper, manganese, and selenium metabolism in thyroid disease. Am J Clin Nutr 1984; 40: 26-35
  • 21 Reglinski J, Smith WE, Wilson R, Halls DJ, McKillop JH, Thomson JA. Selenium in Graves’ disease. Clin Chim Acta 1992; 211: 189-190
  • 22 Bulow Pedersen I, Knudsen N, Carle A, Schomburg L, Kohrle J, Jorgensen T, Rasmussen LB, Ovesen L, Laurberg P. Serum selenium is low in newly diagnosed Graves’ disease: a population-based study. Clin Endocrinol (Oxf) 2013; 79: 584-590
  • 23 Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 2011; 364: 1920-1931
  • 24 Calissendorff J, Mikulski E, Larsen EH, Moller M. A Prospective Investigation of Graves’ Disease and Selenium: Thyroid Hormones, Auto-Antibodies and Self-Rated Symptoms. Eur Thyroid J 2015; 4: 93-98
  • 25 Watt T, Cramon P, Bjorner JB, Bonnema SJ, Feldt-Rasmussen U, Gluud C, Gram J, Hansen JL, Hegedus L, Knudsen N, Bach-Mortensen P, Nolsoe R, Nygaard B, Pociot F, Skoog M, Winkel P, Rasmussen AK. Selenium supplementation for patients with Graves’ hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial. Trials 2013; 14: 119
  • 26 Banga JP, Moshkelgosha S, Berchner-Pfannschmidt U, Eckstein A. Modeling Graves’ Orbitopathy in Experimental Graves' Disease. Horm Metab Res 2015; 47: 797-803
  • 27 Li C, Tan J, Zhang G, Meng Z, Wang R, Li W, Zheng W. Risk factors of hyperthyroidism with hepatic function injury: a 4-year retrospective study. Horm Metab Res 2015; 47: 209-213
  • 28 Furmaniak J, Sanders J, Nunez Miguel R, Rees Smith B. Mechanisms of Action of TSHR Autoantibodies. Horm Metab Res 2015; 47: 735-752
  • 29 Pujol-Borrell R, Gimenez-Barcons M, Marin-Sanchez A, Colobran R. Genetics of Graves’ Disease: Special Focus on the Role of TSHR Gene. Horm Metab Res 2015; 47: 753-766
  • 30 Khong JJ, Goldstein RF, Sanders KM, Schneider H, Pope J, Burdon KP, Craig JE, Ebeling PR. Serum selenium status in Graves’ disease with and without orbitopathy: a case-control study. Clin Endocrinol (Oxf) 2014; 80: 905-910
  • 31 Wertenbruch T, Willenberg HS, Sagert C, Nguyen TB, Bahlo M, Feldkamp J, Groeger C, Hermsen D, Scherbaum WA, Schott M. Serum selenium levels in patients with remission and relapse of Graves’ disease. Med Chem 2007; 3: 281-284
  • 32 Marcocci C, Leo M, Altea MA. Oxidative stress in Graves’ disease. Eur Thyroid J 2012; 1: 80-87
  • 33 Salvi M, Campi I. Medical Treatment of Graves’ Orbitopathy. Horm Metab Res 2015; 47: 779-788
  • 34 Vrca VB, Skreb F, Cepelak I, Romic Z, Mayer L. Supplementation with antioxidants in the treatment of Graves’ disease; the effect on glutathione peroxidase activity and concentration of selenium. Clin Chim Acta 2004; 341: 55-63
  • 35 Duntas LH. The evolving role of selenium in the treatment of Graves’ disease and ophthalmopathy. J Thyroid Res 2012; 2012: 736161
  • 36 Drutel A, Archambeaud F, Caron P. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol (Oxf) 2013; 78: 155-164
  • 37 Wimmer I, Hartmann T, Brustbauer R, Minear G, Dam K. Selenium levels in patients with autoimmune thyroiditis and controls in lower Austria. Horm Metab Res 2014; 46: 707-709
  • 38 Winther KH, Watt T, Bjorner JB, Cramon P, Feldt-Rasmussen U, Gluud C, Gram J, Groenvold M, Hegedus L, Knudsen N, Rasmussen AK, Bonnema SJ. The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial. Trials 2014; 15: 115